Trial Profile
A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2021
Price :
$35
*
At a glance
- Drugs BI 836880 (Primary)
- Indications Breast cancer; Nasopharyngeal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 03 Feb 2021 Status changed from active, no longer recruiting to completed.
- 04 Oct 2020 Planned End Date changed from 31 Oct 2020 to 31 Dec 2020.
- 29 Jun 2020 Planned End Date changed from 30 May 2020 to 31 Oct 2020.